HeartBeam (NASDAQ: BEAT) announced the launch of a pilot study focused on evaluating its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and inadequate blood flow and oxygen supply to tissue, known as ischemia. The study marks a significant step in the development of the HeartBeam patch, which aims to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers seek faster and more accessible ways to identify high-risk patients earlier, HeartBeam’s technology could offer a breakthrough in ambulatory cardiac monitoring.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG while the patient is at home or on the go has the potential to significantly improve early detection and management of coronary artery disease.”
The pilot study represents an important milestone for HeartBeam as it seeks to validate the clinical utility of its patch. Current patch-based monitors typically offer single-lead or limited-lead ECG recordings and are unable to perform ischemia detection, which requires a full 12-lead view of the heart’s electrical activity. HeartBeam’s patch aims to provide on-demand 12-lead ECG capabilities, giving physicians a more comprehensive picture of a patient’s cardiac health over an extended monitoring period.
If successful, the HeartBeam patch could transform the standard of care for patients with known or suspected coronary artery disease. The ability to detect ischemia early could lead to timely interventions, potentially preventing heart attacks and reducing mortality. For healthcare systems, earlier detection could also lower costs associated with emergency cardiac care and hospitalizations.
The broader implications for the cardiac monitoring market are significant. The $2 billion long-term continuous monitor and MCT market has seen limited innovation in ischemia detection, leaving a gap that HeartBeam aims to fill. By offering a patch that can generate on-demand 12-lead ECGs, HeartBeam could capture a substantial share of this market, particularly among patients who require prolonged monitoring but cannot remain tethered to traditional Holter monitors or event recorders.
HeartBeam’s announcement is based on a press release from NewMediaWire. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT. Forward-looking statements in the release involve risks and uncertainties, including those set forth in the company’s filings with the SEC, and actual results may differ materially.
